Dr Brian Rini, of Vanderbilt University Medical Center, presents highlights in renal cell cancer (RCC) from the 2022 Annual Meeting of the American Society of Clinical Oncology.
Dr Rini focuses first on data from the EVEREST study, which was launched in 2011 to examine the effect of adjuvant treatment using an oral mTOR inhibitor. Dr Rini explains why the study's outcomes may fail to affect clinical practice, despite findings that showed improved recurrence-free survival in patients with very high-risk disease.
Next, Dr Rini reviews the results of a study testing whether the recombinant fusion protein dimer batiraxcept, as monotherapy or in combination with the standard of care, could inhibit AXL overexpression in metastatic clear cell RCC. In addition to the trial's endpoints, he discusses the study's "intriguing biomarker data" that also merit attention.
He then discusses a subsequent analysis of the CheckMate 9ER trial which examined the relationship between the depth of response and clinical outcomes as a potential biomarker in patients with previously untreated RCC.
Finally, Dr Rini touches on the CALYPSO study, a phase 2 trial of immunotherapy agents in combination with durvalumab and a potent MET inhibitor, which failed to provide additional benefit.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Highlights in Renal Cell Carcinoma From ASCO 2022 - Medscape - Jul 05, 2022.
Comments